Cocrystal Pharma, Inc. (COCP) Stock Price & Analysis
Cocrystal Pharma, Inc. (COCP) fell 2.17% to USD 0.9 as of July 25, 2026 at 05:20 UTC, according to Nexqual real-time market data.
COCP last closed at USD 0.92; the session ranged USD 0.9–0.96 on volume of 37,855 shares. Market capitalization is $12.41M, with a 52-week range of USD 0.86–2.67 (NCM). Source: Nexqual, July 25, 2026 at 05:20 UTC.
Key Statistics (as of July 25, 2026 at 05:20 UTC)
| Price | USD 0.9 |
|---|---|
| Change | ▼ 2.17% (down) |
| Previous Close | USD 0.92 |
| Open | USD 0.95 |
| Day Range | USD 0.9 – 0.96 |
| 52-Week Range | USD 0.86 – 2.67 |
| Volume | 37,855 shares |
| Market Cap | $12.41M |
| Exchange | NCM |
Technical Analysis (COCP)
Nexqual's technical model rates COCP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.26 (neutral) |
| vs SMA50 | Below (USD 1.04) |
| MACD | -0.04 (negative) |
Analyst Ratings (COCP)
Wall Street analysts rate COCP "None" based on 2 analysts, with a mean price target of USD 9 (range USD 8–10), per Nexqual as of July 25, 2026 at 05:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 9 |
| High Target | USD 10 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (COCP)
| EPS Estimate | USD -0.17 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.17 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.22 ▲ beat |
| 2025-06-30 | USD -0.2 vs est -0.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Financials & Fundamentals (COCP)
| Total Revenue | $225,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1047.11% |
| Profit Margin | +0.00% |
| ROE | -154.62% |
| Debt / Equity | 34.6 |
| Current Ratio | 2.66 |
| Total Cash | $4.68M |
| Total Debt | $1.42M |
| Free Cash Flow | $-4.41M |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Financial Health Score (COCP)
Nexqual rates Cocrystal Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -155%, ROA -62.4% |
Ownership (COCP)
| Insider Ownership | +30.73% |
|---|---|
| Institutional Ownership | +5.63% |
| Shares Outstanding | 13.79M |
| Float | 9.12M |
| Short % of Float | +3.82% |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Leadership (COCP)
Cocrystal Pharma, Inc. is led by James R. Sapirstein M.B.A., R.Ph. (age 64), Chief Executive Officer, per Nexqual as of July 25, 2026 at 05:20 UTC.
| Chief Executive Officer | James R. Sapirstein M.B.A., R.Ph. (age 64) |
|---|---|
| Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | Roger D. Kornberg (age 78) |
| Chief Scientific Officer, Co-Founder & President | Sam Lee (age 65) |
Major Backers & Investors (COCP)
Notable institutional backers of Cocrystal Pharma, Inc. include Renaissance Technologies, Fidelity, T3 Companies, LLC, according to Nexqual as of July 25, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.9% |
| Fidelity | 0.53% |
| T3 Companies, LLC | 0.37% |
| Xtx Topco Ltd | 0.26% |
| Neuberger Berman Group, LLC | 0.23% |
| Two Sigma Securities, LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.65% |
| Geode Capital | 0.65% |
| BlackRock | 0.53% |
| State Street | 0.15% |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
From Cocrystal Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- In August 2025 we presented favorable safety and tolerability Phase 1 data from all CDI-988 doses, including the high-dose 1200 mg cohort, at the 2025 Military Health System Research Symposium (MHSRS).   In September 2025 we received a Study May Proceed Letter from the FDA to conduct a Phase 1b challenge study in the U.S. evaluating CDI-988 as a norovirus preventive and treatment.
- In addition, the FDA issued emergency use authorization (EUA) for several antibody and antiviral therapeutics, including and Lagevrio™ (molnupiravir).   We continue pursuing the development of novel antiviral compounds for the treatment of coronavirus infections using our established proprietary drug discovery platform.
- We developed our proprietary structure-based drug design under the guidance of Dr.
- To discover and design these direct-acting antiviral drug candidates, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how.
Partnerships
- As of the date of this Report, it appears that the Company will seek to arbitrate the dispute as required under the agreement with the CRO.
- Aspects of this program were developed in collaboration with Merck, which is legally protecting the intellectual property of the collaboration compounds.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | USD 0.25 | ▼ 0.4% |
| AYTU | Aytu BioPharma, Inc. | USD 2.16 | ▲ 0% |
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| IBIO | iBio, Inc. | USD 1.43 | ▲ 3.62% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:20 UTC. This page is informational and not investment advice.